These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 27074786)

  • 1. Are Vancomycin Trough Concentrations of 15 to 20 mg/L Associated With Increased Attainment of an AUC/MIC ≥ 400 in Patients With Presumed MRSA Infection?
    Hale CM; Seabury RW; Steele JM; Darko W; Miller CD
    J Pharm Pract; 2017 Jun; 30(3):329-335. PubMed ID: 27074786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of vancomycin AUC/MIC dosing vs traditional trough dosing and incidence of acute kidney injury at a rural community hospital.
    McClure S; McElroy L; Gugkaeva Z
    Am J Health Syst Pharm; 2024 May; 81(11):e283-e288. PubMed ID: 38253056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Relationship Between Vancomycin Trough Concentrations and AUC/MIC Ratios in Pediatric Patients: A Qualitative Systematic Review.
    Tkachuk S; Collins K; Ensom MHH
    Paediatr Drugs; 2018 Apr; 20(2):153-164. PubMed ID: 29344778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vancomycin Trough Concentration as a Predictor of Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: A Meta-analysis of Observational Studies.
    Prybylski JP
    Pharmacotherapy; 2015 Oct; 35(10):889-98. PubMed ID: 26497475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
    Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?
    Patel K; Crumby AS; Maples HD
    Paediatr Drugs; 2015 Apr; 17(2):97-103. PubMed ID: 25644329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of a Vancomycin Pharmacokinetic Model and Trough Serum Concentrations in Pediatric Patients.
    Ploessl C; White C; Manasco K
    Pediatr Infect Dis J; 2015 Oct; 34(10):e244-7. PubMed ID: 26121203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.
    Frymoyer A; Guglielmo BJ; Hersh AL
    Pediatr Infect Dis J; 2013 Oct; 32(10):1077-9. PubMed ID: 23652479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
    Song KH; Kim HB; Kim HS; Lee MJ; Jung Y; Kim G; Hwang JH; Kim NH; Kim M; Kim CJ; Choe PG; Chung JY; Park WB; Kim ES; Park KU; Kim NJ; Kim EC; Oh MD
    Int J Antimicrob Agents; 2015 Dec; 46(6):689-95. PubMed ID: 26555059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
    Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
    J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.
    Kullar R; Davis SL; Levine DP; Rybak MJ
    Clin Infect Dis; 2011 Apr; 52(8):975-81. PubMed ID: 21460309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vancomycin: we can't get there from here.
    Patel N; Pai MP; Rodvold KA; Lomaestro B; Drusano GL; Lodise TP
    Clin Infect Dis; 2011 Apr; 52(8):969-74. PubMed ID: 21460308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examining the Relationship Between Vancomycin Area Under the Concentration Time Curve and Serum Trough Levels in Adults With Presumed or Documented Staphylococcal Infections.
    Clark L; Skrupky LP; Servais R; Brummitt CF; Dilworth TJ
    Ther Drug Monit; 2019 Aug; 41(4):483-488. PubMed ID: 30817704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of pharmacodynamic target attainment with vancomycin treatment of bacteremia due to Staphylococcus aureus methicillin resistant].
    Lepe JA; Gil-Navarro MV; Santos-Rubio MD; Bautista J; Aznar J
    Rev Esp Quimioter; 2010 Mar; 23(1):43-7. PubMed ID: 20232023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Therapeutic Vancomycin Monitoring in Taiwan.
    Chen TT; Liu MP; Sun HC
    Microbiol Spectr; 2022 Apr; 10(2):e0156221. PubMed ID: 35412391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion from Vancomycin Trough Concentration-Guided Dosing to Area Under the Curve-Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center.
    Meng L; Wong T; Huang S; Mui E; Nguyen V; Espinosa G; Desai J; Holubar M; Deresinski S
    Pharmacotherapy; 2019 Apr; 39(4):433-442. PubMed ID: 30739349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of source of infection and vancomycin AUC0-24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Ghosh N; Chavada R; Maley M; van Hal SJ
    Clin Microbiol Infect; 2014 Dec; 20(12):O1098-105. PubMed ID: 24890030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-Dose Vancomycin Pharmacokinetics Versus Empiric Dosing on Area-Under-the-Curve Target Attainment in Critically Ill Patients.
    Flannery AH; Delozier NL; Effoe SA; Wallace KL; Cook AM; Burgess DS
    Pharmacotherapy; 2020 Dec; 40(12):1210-1218. PubMed ID: 33176005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Vancomycin Area-Under-the-Curve Dosing Versus Trough Target-Based Dosing in Obese and Nonobese Patients With Methicillin-Resistant
    Covvey JR; Erickson O; Fiumara D; Mazzei K; Moszczenski Z; Slipak K; Nemecek BD; Zimmerman DE; Guarascio AJ
    Ann Pharmacother; 2020 Jul; 54(7):644-651. PubMed ID: 31888350
    [No Abstract]   [Full Text] [Related]  

  • 20. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
    Abdel Hadi O; Al Omar S; Nazer LH; Mubarak S; Le J
    J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.